Cargando…
The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990150/ https://www.ncbi.nlm.nih.gov/pubmed/33928222 http://dx.doi.org/10.1093/abt/tbz005 |
| _version_ | 1783669022399660032 |
|---|---|
| author | Deng, Mi |
| author_facet | Deng, Mi |
| author_sort | Deng, Mi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7990150 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79901502021-04-28 The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China Deng, Mi Antib Ther News and Views Oxford University Press 2019-03-13 /pmc/articles/PMC7990150/ /pubmed/33928222 http://dx.doi.org/10.1093/abt/tbz005 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Antibody Therapeutics. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | News and Views Deng, Mi The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China |
| title | The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China |
| title_full | The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China |
| title_fullStr | The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China |
| title_full_unstemmed | The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China |
| title_short | The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China |
| title_sort | approval of sintilimab for classical hodgkin's lymphoma: views and perspectives of anti-pd-1/pd-l1 antibodies in china |
| topic | News and Views |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990150/ https://www.ncbi.nlm.nih.gov/pubmed/33928222 http://dx.doi.org/10.1093/abt/tbz005 |
| work_keys_str_mv | AT dengmi theapprovalofsintilimabforclassicalhodgkinslymphomaviewsandperspectivesofantipd1pdl1antibodiesinchina AT dengmi approvalofsintilimabforclassicalhodgkinslymphomaviewsandperspectivesofantipd1pdl1antibodiesinchina |